Our detailed analysis showed that pharmaceuticals and over the counter drugs were being manufactured for the Chinese domestic and European markets. Contract manufacturing was also occuring for over the counter drugs being sold in "China".
For each drug, the supply of raw materials would come from Europe until production operated for a few months. Excipients and basic chemicals would then be transitioned to Chinese suppliers who were trained by the six sigma process leader in lean manufacturing and current good manufacturing practices. Although active ingredients would only be sourced from Europe, the company had a capital investment plan to triple revenues in five years.
Primary Impact advised the client to work closely with the provincial drug agency and establish an anti-counterfeit department to conduct regular fraud investigations. We also suggested stressing the value of highly skilled job creation and supplier training to the Chinese government who awards pharmaceutical contracts.
The client integrated our analysis and advice into their China plan.
They received a Certificate from the Chinese FDA and are supplying pharmaceuticals to hospitals. Supplying pharmaceuticals to Europe from China is being considered. Click link to learn more about Primary Impact's pharmaceutical industry practice.
